Persistence of antibodies 1 year after sequential administration of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine in adults

Vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed ≥ 1 year by the 23-valent pneumococcal polysaccharide vaccine (PPSV23) is recommended for immunocompetent adults ≥ 65 years of age in the United States. This study assessed antipneumococcal opsonophagocytic activity (OPA)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Hum Vaccin Immunother
Auteurs principaux: Schmoele-Thoma, Beate, van Cleeff, Martin, Greenberg, Richard N., Gurtman, Alejandra, Jones, Thomas R., Sundaraiyer, Vani, Gruber, William C., Scott, Daniel A.
Format: Artigo
Langue:Inglês
Publié: Taylor & Francis 2019
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6605716/
https://ncbi.nlm.nih.gov/pubmed/30648932
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1538618
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires